Clinical research progress of CAR-T cell therapy in autoimmune neurological diseases
10.3760/cma.j.cn115354-20250513-00278
- VernacularTitle:嵌合抗原受体T细胞疗法在神经系统自身免疫性疾病中的临床研究进展
- Author:
Zhenzhen YANG
1
;
Mengkai GUO
1
;
Jinghan NIU
1
;
Mengyao GUO
1
;
Kunda SHI
1
;
Xinjing LIU
1
;
Jun WU
1
Author Information
1. 郑州大学第一附属医院神经内科，郑州 450052
- Publication Type:Journal Article
- Keywords:
Chimeric antigen receptor T-cell therapy;
Autoimmune disease;
B cell;
Nervous system;
Genetic engineering
- From:
Chinese Journal of Neuromedicine
2025;24(11):1145-1153
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune diseases of the nervous system are a category of conditions in which a malfunction of the body's immune system leads to damage of nerve tissues, with B cells playing a critical role in their pathogenesis. Currently, the therapeutic approaches used in clinical practice (such as monoclonal antibodies targeting B cells) can effectively control the progression of these diseases, but fail to achieve a radical cure. Chimeric antigen receptor (CAR)-T cell therapy uses genetic engineering to modify T cells derived from either patients or donors, enabling them to specifically target and durably eliminate peripheral B cells, which might remit or even functionally cure these diseases. Currently, multiple clinical studies on efficacy and safety of CAR-T cell therapy in neurological autoimmune diseases have been carried out successively, and initial results have been achieved. This article reviews the clinical research progress in this field, discusses its application prospects and challenges, aiming to provide some references for in-depth research in this area.
